PION PION 深 滬
等待開盤 05-13 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 0
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Oculis Holding AG will present updates on its late-stage pipeline and key unmet medical needs in ophthalmology at the ARVO 2026 Annual Meeting. Highlights include findings from the DME AWARE Delphi Study emphasizing the need for non-invasive therapies for diabetic macular edema (DME), post-hoc analysis of Privosegtor's impact on retinal ganglion cell loss in optic neuritis, and a corporate update on upcoming milestones. The company is advancing O...
05-01 08:00
Boston Scientific says CHAMPION-AF trial shows WATCHMAN FLX beats anticoagulants on bleeding risk
Boston Scientific says CHAMPION-AF trial shows WATCHMAN FLX beats anticoagulants on bleeding risk Boston Scientific highlighted late-breaking clinical trial results already presented at American College of Cardiology meeting, with simultaneous publication in New England Journal of Medicine. CHAMPION
04-22 19:53
BRIEF-Flagship Pioneering, Amazon Web Services Announced Strategic Collaboration
BRIEF-Flagship Pioneering, Amazon Web Services Announced Strategic Collaboration April 1 (Reuters) - Amazon.com Inc AMZN.O : FLAGSHIP PIONEERING - CO, AMAZON WEB SERVICES ANNOUNCED STRATEGIC COLLABORATION FLAGSHIP PIONEERING - COLLABORATION TO ACCELERATE DRUG DISCOVERY AND LIFE SCIENCES INNOVATION S
04-01 18:56
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Oculis Holding AG announced that its neuroprotective candidate, Privosegtor, has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of optic neuritis (ON), a rare, sight-threatening condition. This follows a Breakthrough Therapy designation from the U.S. FDA in January 2026, highlighting the potential of Privosegtor as the first neuroprotective therapy for ON. The designation is supported ...
03-31 08:00
Boston Scientific Drops Despite Encouraging Trial Readouts
Boston Scientific shares fall after WATCHMAN FLX and EKOS trial updates, as analysts adjust ratings and price targets despite positive data.
03-31 00:44
波士顿科学(BSX)股票3月30日收盘下跌9.06%：关键驱动因素揭晓
• 分析师因担心增长放缓而下调该股评级。 • 该公司2026年的增长预测低于市场普遍预期。 • 法律风险和参差不齐的临床数据影响了股价表现。
03-30 20:16
波士顿科学(BSX)股票3月26日盘中上涨3.66%：背后推手曝光
• Stifel重申对波士顿科学的“买入”评级，目标价为90.00美元。 • 分析师维持积极评级，目标价区间在92美元至120美元之间。 • 以145亿美元收购Penumbra预计将提振其心血管产品组合。
03-26 19:16
Boston Scientific Corp Stock (BSX) Moved Up by 3.66% on Mar 26: Key Drivers Unveiled
• Stifel reiterated a Buy rating with a $90.00 price target on Boston Scientific. • Analysts maintain positive ratings with price targets ranging from $92 to $120. • Acquisition of Penumbra for $14.5 billion is expected to boost cardiovascular portfolio.
03-26 19:15
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Oculis Holding AG announced the presentation of Phase 2 ACUITY trial results for Privosegtor at the NANOS 2026 Annual Meeting, showcasing significant improvements in low-contrast visual acuity and neuroprotective effects in patients with optic neuritis (ON). Privosegtor, a novel peptoid small molecule, has the potential to become the first neuroprotective therapy for ON, with Breakthrough Therapy designation from the FDA. The trial results highli...
03-16 09:00
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
Oculis Holding AG reported significant achievements in 2025, including clinical progress across its late-stage portfolio and a strategic expansion into neuro-ophthalmology. The company highlighted breakthrough therapy designation for Privosegtor in optic neuritis, Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema (DME), and the initiation of Licaminlimab's genotype-based registrational trial for dry eye disease (DED). Cash reserves reac...
03-03 21:05
